HCC70 Xenograft Model Service for Breast Cancer

The HCC70 xenograft model serves as a highly specialized in vivo translational platform designed to evaluate candidate therapies targeting aggressive, TNBC-activated cell signaling pathways. Alfa Cytology delivers a comprehensive, end-to-end HCC70 xenograft model service, combining optimized cell preparation methodologies with precise procedural and inoculation protocols to accelerate your preclinical oncology drug discovery timeline.

Overview of HCC70 Xenograft Model for Breast Cancer

The HCC70 cell line is a well-established human mammary carcinoma model that represents the basal-like molecular subtype of triple-negative breast cancer (TNBC). Derived from a primary ductal carcinoma, this model is molecularly defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. Notably, HCC70 cells exhibit a distinct genomic landscape, including mutated TP53 and a high baseline activation of the EGFR and MAPK pathways, which closely mirrors the aggressive clinical pathology of poorly differentiated human breast tumors. This makes the HCC70 model a crucial preclinical instrument for screening novel targeted small molecules, exploring combination therapies, and assessing therapeutic responses to conventional chemotherapeutic regimens.

When established in vivo as a xenograft in immunocompromised mice, HCC70 cells form solid subcutaneous tumors characterized by steady growth kinetics and reproducible engraftment rates. The model provides an optimized therapeutic window for evaluating longitudinal tumor volume reduction, tumor microenvironment interactions, and drug distribution profile assessments, serving as a dependable screening platform for preclinical discovery.

Fig 1. HzMUC1 antibody binds to MUC1 on the cell surface of TNBC cells. (Li L, et al., 2023)

Cell Line Information: HCC70

The HCC70 cell line maintains a stable epithelial morphology in vitro and reliably preserves its primary triple-negative receptor status and genomic signatures upon in vivo transplantation.

Alfa Cytology is dedicated to upholding the highest benchmarks of scientific precision across all our tumor modeling operations. Our specialized oncology team utilizes fully authenticated cell lines and carefully monitored protocols to safeguard the genetic and phenotypic stability of the HCC70 model throughout the lifecycle of your study.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the HCC70 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC and PK/PD profiling. Leveraging our expertise in basal-like triple-negative breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of HCC70 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the HCC70 xenograft model:

• Cell Culture & Quality Control: HCC70 cells are cultivated in optimized growth media. Comprehensive quality controls, including STR profiling and contamination screening, are performed to guarantee high cell viability and phenotypic identity before inoculation.
• Host Adaptation: Standardized immunocompromised mice are selected based on the study design and allowed to acclimate to our controlled facility parameters to achieve baseline physiological stability.
• Precision Inoculation: A highly viable, calibrated suspension of HCC70 cells is prepared and blended with a biological matrix carrier to optimize cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic (mammary fat pad) routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. HCC70 Xenograft Model Construction Workflow

Case Study - HCC70 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the HCC70 xenograft model was successfully utilized to evaluate the efficacy of a novel small-molecule EGFR inhibitor in triple-negative breast cancer. Our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms under optimized modeling conditions, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent tumor growth inhibition in the treatment group compared to the vehicle control.

Why Choose Alfa Cytology?

Choosing the right partner for your basal-like triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Advanced Modeling Expertise: Broad proficiency in establishing and characterizing a diverse portfolio of human tumor models.
• Stringent Quality Control: All cell lines undergo rigorous authentication, including STR profiling, to secure baseline stability.
• Technical Reproducibility: Optimized inoculation methodologies designed to achieve uniform tumor growth kinetics.
• Comprehensive Readouts: Fully equipped to deliver multi-parametric endpoints, including high-precision tumor tracking and PK/PD tissue processing.
• Scientific Integrity: All studies are executed by a specialized team providing publication-ready data and transparent reporting.

Contact Us

Are you looking to advance your therapeutic pipeline against basal-like, triple-negative breast cancer using the robust HCC70 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.